Stocks TelegraphStocks Telegraph
Stock Ideas

BDX Company Profile and Key Details

NYSE : BDX

Becton Dickinson and

$207.39
-2.63-1.25%
At Close 4:00 PM
68.73
B+ESG ScoreESG Rating

Price Chart

Stock Price Today

Becton, Dickinson and Company (BDX) stock declined over -1.25%, trading at $207.39 on NYSE, down from the previous close of $210.02. The stock opened at $204.84, fluctuating between $200.40 and $211.47 in the recent session.

Stock Snapshot

210.02
Prev. Close
59.09B
Market Cap
200.4
Day Low
36.13
P/E Ratio
5.74
EPS (TTM)
9.13
Cash Flow per Share
204.84
Open
284.91M
Number of Shares
211.47
Day High
99.78%
Free Float in %
87.32
Book Value
3.28M
Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing DateAccepted Date

Annual Report (10-k)

Filing DateAccepted Date

Stock Price History Chart

DateOpenHighLowCloseVolume
Feb 09, 2026204.00211.47200.37207.393.66M
Feb 06, 2026206.76210.70204.90210.022.21M
Feb 05, 2026208.71209.99205.87206.512.82M
Feb 04, 2026207.10213.08205.65207.873.14M
Feb 03, 2026202.69208.64201.92206.502.84M
Feb 02, 2026203.00203.61201.19201.911.95M
Jan 30, 2026201.74204.05200.11203.482.62M
Jan 29, 2026200.46202.06199.00201.091.45M
Jan 28, 2026204.05208.00200.38201.921.69M
Jan 27, 2026201.74205.18201.18203.401.81M
Jan 26, 2026202.73205.49202.25203.421.23M
Jan 23, 2026205.50205.52195.63201.793.43M
Jan 22, 2026206.05207.60204.28206.042.02M
Jan 21, 2026205.07207.54204.13206.181.61M
Jan 20, 2026204.78206.34203.13203.391.57M
Jan 16, 2026207.08209.12206.65207.111.57M
Jan 15, 2026206.54209.27205.57208.352.16M
Jan 14, 2026201.81207.64200.81207.421.41M
Jan 13, 2026202.66203.65198.44201.521.13M
Jan 12, 2026202.80203.57201.35202.741.38M

Contact Details

Franklin Lakes, NJ 07417-1880

United States

https://www.bd.com201 847 6800

About Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.

Company Information

Employees70000
Beta0.28
Sales or Revenue$21.84B
5Y Sales Change%0.322%
Fiscal Year EndsSeptember
SectorHealthcare
IndustryMedical - Instruments & Supplies

Company Overview

Becton, Dickinson and Company (NYSE:BDX) closed at $207.39 USD, losing -$2.63 (-1.25%) from the previous close of $210.02. The stock is currently mid-range between its 52-week high and low $162.29 and $235.34. With a market capitalization of about $59.09 billion, Becton, Dickinson and Company is classified as a large-cap and shows lower-than-market volatility (beta ~0.28). Key stats such as the average daily volume over the past year has been around 2.05 million shares, trading with heavier-than-usual volume. Headquartered in Franklin Lakes, NJ, Becton, Dickinson and Company operates in the Healthcare sector and the Medical - Instruments & Supplies industry. Led by CEO Thomas E. Polen Jr., the company employs approximately 70,000 people and listed since February 21, 1973. Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide.

Technical Performance

Short-term trend indicators are bearishly aligned (SMA20 1.21%, SMA50 3.81%, SMA200 10.79%). The stock’s 14-day RSI is 57.17 (neutral), while the ATR of 5.2 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -11.88% below its high and over 27.79% above its low. Average 10-day trading volume of 2.75 million shares is slightly above the 3-month average of 1.98 million, indicating heightened recent market interest.

Dividend & Fair Value

Becton, Dickinson and Company last paid a dividend of 4.17 per share, this equals a trailing yield of roughly 1.62%. Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $668.55. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Becton, Dickinson and Company generated EPS of $5.83 over the past year. Five-year average earnings growth is 16.45%. Wall Street analysts project EPS growth of 3.85% annually over the next five years. The latest quarter delivered EPS of $3.96. The next quarter is forecast at $2.81. Next year's EPS is expected at $11.12. Analyst sentiment is neutral. Analyst rating data shows there are 4 Strong Buy ratings, 1 Buy ratings, 9 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $279.00 to $184.00. The high target offers 34.53% upside. The low target suggests -11.28% downside. The mean target is $213.00. This offers 2.71% upside. Becton, Dickinson and Company earnings surprise history is a consistent trend of beating forecasts. The quarter that ended November 06, 2025, missed forecasts by 1.02%. The prior quarter beat by 8.24%. Over the last six quarters, Apple has recorded several small beats. These include 5.74% in August 01, 2024.

Shareholding & Insider Activity

Becton, Dickinson and Company has 286.63 million shares outstanding. The public float is 285.99 million shares, elevated short interest at 1.34% of float. This equals 3.83 million shares. The short ratio is 2.4 days. Institutional investors hold 92.78% of the float. Insiders own 0.57%. FORLENZA VINCENT A holds 208.86 thousand shares, RING TIMOTHY M has 93.69 thousand shares and SCOTT BERTRAM L has 35.82 thousand shares. Over the past six months, insider transactions show net selling. They sold 3.17 thousand shares across 10 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Becton Dickinson and generated $21.84B in revenue, or $76.06 per share. Gross margin was 45.44%, operating margin 11.80%, and net profit margin 7.68%. Returns are modest, with ROA at 3.03% and ROE at 6.61%.
On valuation metrics, Becton Dickinson and trades at a P/E of 33.69, P/S of 2.70 and P/B of 1.08. The current ratio is 8.61 and quick ratio is 4.78. Operationally, the company’s inventory turnover is 2.91 and cash conversion cycle is 167.16 days. Debt-to-equity is 0.33, supported by a cash flow-to-debt ratio of 0.19.

Quarterly Financial Highlights

For the quarter ended Sep 30, 2025, Becton Dickinson and posted revenue of $21.84B, down slightly from $20.18B in the prior quarter. Gross profit was $9.92B (margin 45.44%). Operating income was $2.58B (margin 11.8%). Net income was$1.68B (EPS $5.84).
The company ended the quarter with $859.00M in cash and short-term investments, a total debt of $19.18B, and net debt of $18.33B. Total assets were $55.33B, with equity of $25.39B. Financials further reflected stability, with operating cash flow of $3.43B, free cash flow of $2.67B, and capital expenditures of - $760.00M.

Frequently Asked Questions

What is the current Becton, Dickinson and Company (BDX) stock price?
Becton, Dickinson and Company (NYSE: BDX) stock price is $207.39 in the last trading session. During the trading session, BDX stock reached the peak price of $211.47 while $200.40 was the lowest point it dropped to. The percentage change in BDX stock occurred in the recent session was -1.25% while the dollar amount for the price change in BDX stock was - $2.63.
BDX's industry and sector of operation?
The NYSE listed BDX is part of Medical - Instruments & Supplies industry that operates in the broader Healthcare sector. Becton, Dickinson and Company designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Who are the executives of BDX?
Ms. Elizabeth McCombs
Executive Vice President & Chief Technology Officer
Ms. Denise Fleming
Executive Vice President of Technology & Global Services and Chief Information Officer
Mr. Christopher J. DelOrefice
Executive Vice President & Chief Financial Officer
Ms. Shana Carol Neal
Executive Vice President & Chief People Officer
Ms. Francesca M. DeMartino
Senior Vice President & Head of Investor Relations
Michelle Quinn
Senior Vice President and Chief Ethics & Compliance Officer
Mr. Christopher DelOrefice
Executive Vice President & Chief Financial Officer
Mr. Thomas E. Polen Jr.
Pres, Chief Executive Officer & Chairman
Troy Kirkpatrick
Vice President of PR
Dr. Joseph M. Smith F.A.C.C, M.D., Ph.D.
Senior Vice President, Chief Scientific Officer & Co-Chair of Scientific Advisory Board
Mr. David B. Hickey
Executive Vice President & Pres of Life Sciences Segment
Ms. Michelle Quinn
Executive Vice President & Gen. Counsel
Mr. Thomas J. Spoerel
Senior Vice President, Controller & Chief Accounting Officer
How BDX did perform over past 52-week?
BDX's closing price is 27.79% higher than its 52-week low of $162.29 where as its distance from 52-week high of $235.34 is -11.88%.
How many employees does BDX have?
Number of BDX employees currently stands at 70,000.
Link for BDX official website?
Official Website of BDX is: https://www.bd.com
How do I contact BDX?
BDX could be contacted at phone 201 847 6800 and can also be accessed through its website. BDX operates from 1 Becton Drive, Franklin Lakes, NJ 07417-1880, United States.
How many shares of BDX are traded daily?
BDX stock volume for the day was 3.28M shares. The average number of BDX shares traded daily for last 3 months was 2.05M.
What is the market cap of BDX currently?
The market value of BDX currently stands at $59.09B with its latest stock price at $207.39 and 284.91M of its shares outstanding.
logo

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep

stockstelegraph

Don't have an account?

stockstelegraph

Don't have an account?

stockstelegraph

Already have an account?

stockstelegraph
Smart Screening Tools for Exceptional Returns
stockstelegraph

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!
stockstelegraph